Focus on medical science and technology for public health
See more +
Be realistic,Innovate,Responsibility,Multi-win
See more +
Become a leading technological and innovative pharmaceutical enterprise
See more +Shandong Yumankun Biotechnology Co., Ltd.
National high-tech enterprises, provincial specialized special new small and medium-sized enterprises, and has passed the ISO9001 quality management system certification.
Company is committed to the research and development of new drugs and high-tech development of medicine. Since its establishment, it has completed more than 30 scientific and technological achievements transformation, and has many varieties of generic drugs covering high-tech barriers, second-class new drugs and a variety of improved and innovative drugs. Its varieties cover neurology, respiratory, nephrology, gastroenterology and other fields. With more than 3000 square meters of R & D center, it is expected that in the next 3 to 5 years, the company will build a pharmaceutical innovation base integrating R & D, investment and operation. In early 2021, the company signed a capital increase and share expansion cooperation agreement with Shandong Kangmeile Pharmaceutical Technology Co., Ltd., accounting for 60% of the shares. Shandong kangmeile pharmaceutical technology co., ltd. has a laboratory area of 3200 square meters. it is Jinan's 5150 talent enterprise, overseas student enterprise, national high-tech enterprise, specialized and special new enterprise.
Company was established in 2018
Has more than 3000 square meters of research and development center
Sales area covers 32 provinces and autonomous regions
30 honorary qualifications
Product display
The company is committed to new drug research and development and pharmaceutical high-tech development, since its inception, has completed the transformation of more than 30 scientific and technological achievements
News
Focus on medical science and technology, for the public health
Nov 08,2023
On November 6, the ninth batch of national drug centralized volume purchasing meeting was held in Shanghai. Shandong Yumangkun Biotechnology Co., Ltd. consistency evaluation over the evaluation of the product piracetam injection was selected.
Sep 27,2023
Good News｜Shandong Yumankun Biotechnology Co., Ltd. won the eighth batch of national centralized purchasing of pharmaceutical products.
Sep 09,2023
Circular of the National Medical Security Bureau on Further Deepening the Intelligent Audit and Monitoring of the Medical Security Fund
Address: Room 2602, Huiyuan Building, 38 Huaneng Road, Lixia District, Jinan City, Shandong Province
©Shandong Yumankun Biotechnology Co., Ltd.